Cylocide



Indications and Reactions:

Role Indications Reactions
Secondary
Neoplasm Malignant 22.8%
Product Used For Unknown Indication 17.2%
Prophylaxis 11.1%
Acute Lymphocytic Leukaemia 8.2%
Stem Cell Transplant 6.3%
Acute Promyelocytic Leukaemia 4.8%
T-cell Type Acute Leukaemia 4.7%
Adult T-cell Lymphoma/leukaemia 3.8%
Infection Prophylaxis 3.1%
Lymphoma 2.3%
Drug Use For Unknown Indication 2.1%
Acute Myeloid Leukaemia 2.1%
Acute Myeloid Leukaemia Recurrent 2.1%
Febrile Neutropenia 1.8%
Prophylaxis Of Nausea And Vomiting 1.6%
Precursor T-lymphoblastic Lymphoma/leukaemia 1.3%
Chronic Myeloid Leukaemia 1.3%
B-cell Lymphoma 1.2%
Constipation 1.2%
Mycosis Fungoides 1.2%
White Blood Cell Count Decreased 16.9%
Myelodysplastic Syndrome 10.2%
Thrombocytopenia 8.5%
Vomiting 8.5%
Pancytopenia 5.1%
Pneumonia 5.1%
Pyrexia 5.1%
Renal Failure Acute 5.1%
Stomatitis 5.1%
Febrile Neutropenia 4.2%
Sepsis 4.2%
Treatment Related Secondary Malignancy 3.4%
Tumour Lysis Syndrome 3.4%
Diarrhoea 2.5%
Leukoencephalopathy 2.5%
Pleural Effusion 2.5%
Stevens-johnson Syndrome 2.5%
Azoospermia 1.7%
Cardiac Failure 1.7%
Disease Progression 1.7%
Concomitant
Neoplasm Malignant 37.7%
Acute Myeloid Leukaemia 8.8%
Drug Use For Unknown Indication 7.9%
Prophylaxis 6.6%
Acute Lymphocytic Leukaemia 5.6%
T-cell Type Acute Leukaemia 4.9%
Infection Prophylaxis 3.4%
Myelodysplastic Syndrome 2.8%
Product Used For Unknown Indication 2.7%
Packed Red Blood Cell Transfusion 2.6%
Platelet Transfusion 2.6%
Stem Cell Transplant 2.6%
Chronic Myeloid Leukaemia 2.4%
Acute Promyelocytic Leukaemia 1.5%
Convulsion Prophylaxis 1.4%
Immunosuppression 1.4%
Sepsis 1.4%
B-cell Lymphoma 1.3%
Infection 1.3%
Prophylaxis Against Graft Versus Host Disease 1.1%
White Blood Cell Count Decreased 22.1%
Sepsis 11.4%
Pleural Effusion 10.7%
Cytomegalovirus Viraemia 6.7%
Systemic Candida 5.4%
Pulmonary Alveolar Haemorrhage 4.7%
Engraft Failure 4.0%
Febrile Neutropenia 4.0%
Purpura 3.4%
Renal Disorder 3.4%
Respiratory Failure 3.4%
Rhabdomyolysis 3.4%
Torsade De Pointes 3.4%
Acute Myeloid Leukaemia 2.0%
Fungaemia 2.0%
Memory Impairment 2.0%
Myelodysplastic Syndrome 2.0%
Pneumonia 2.0%
Pulmonary Hypertension 2.0%
Pyrexia 2.0%
Interacting
Acute Myeloid Leukaemia 28.8%
Prophylaxis 28.8%
Febrile Neutropenia 17.3%
Drug Use For Unknown Indication 11.5%
Antifungal Prophylaxis 7.7%
Menorrhagia 5.8%
Drug Interaction 40.0%
Menorrhagia 40.0%
Device Occlusion 20.0%